Journal Article

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Wharton, Sean, Blevins, Thomas, Rosenstock, Julio, Liu, Rong, Connery, Lisa, Haupt, Axel, Konig, Manige, Raha, Sohini, Ma, Xiaosu, Kazda, Christof, Mather, Kieren J., Robins, Deborah, Pratt, Edward

2023

Overview

Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes. Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks. The percentage change from baseline in body weight was assessed at week 26 (primary end point) and at week 36 (secondary end point). A total of 272 participants underwent randomization. At baseline, the mean body weight was 108.7 kg, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 37.9. At week 26, the mean change from baseline in body weight ranged from -8.6% to -12.6% across the orforglipron dose cohorts and was -2.0% in the placebo group. At week 36, the mean change ranged from -9.4% to -14.7% with orforglipron and was -2.3% with placebo. A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo. The use of orforglipron led to improvement in all prespecified weight-related and cardiometabolic measures. The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation, and led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts. The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class. Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. (Funded by Eli Lilly; GZGI ClinicalTrials.gov number, NCT05051579.).

• Publisher: Massachusetts Medical Society
• Subject: Administration, Oral / Adult / Adverse events / Agonists / Anti-Obesity Agents - administration & dosage / Anti-Obesity Agents - adverse effects / Anti-Obesity Agents - pharmacology / Anti-Obesity Agents - therapeutic use / Body weight / Clinical Medicine / Clinical Medicine General / Diabetes / Diabetes mellitus / Diabetes Mellitus, Type 2 / Diet / Double-Blind Method / Double-blind studies / Endocrinology / Gastroenterology / GLP-1 receptor agonists / Glucagon / Glucagon-like peptide 1 / Glucagon-Like Peptide-1 Receptor Agonists / Glucagon-Like Peptides / Humans / Hypoglycemic Agents - therapeutic use / Nutrition / Obesity / Obesity - chemically induced / Obesity - complications / Obesity - drug therapy / Overweight / Pharmacokinetics / Placebos / Risk factors / Statistical analysis / Weight control / Weight Loss - drug effects